News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
753,462 Results
Type
Article (53783)
Company Profile (473)
Press Release (699206)
Section
Business (217959)
Career Advice (2866)
Deals (37395)
Drug Delivery (119)
Drug Development (87087)
Employer Resources (183)
FDA (17097)
Job Trends (16069)
News (369882)
Policy (35601)
Tag
Academia (2900)
Alliances (53311)
Alzheimer's disease (1416)
Approvals (17051)
Artificial intelligence (225)
Bankruptcy (385)
Best Places to Work (12332)
Biotechnology (354)
Breast cancer (241)
Cancer (1821)
Cardiovascular disease (147)
Career advice (2399)
CAR-T (133)
Cell therapy (386)
Clinical research (69840)
Collaboration (716)
Compensation (381)
COVID-19 (2786)
C-suite (173)
Data (1669)
Diabetes (228)
Diagnostics (6644)
Earnings (88662)
Employer resources (159)
Events (120021)
Executive appointments (598)
FDA (18033)
Funding (640)
Gene therapy (278)
GLP-1 (753)
Government (4827)
Healthcare (20155)
Infectious disease (2905)
Inflammatory bowel disease (133)
Interviews (554)
IPO (17150)
Job creations (4218)
Job search strategy (1984)
Layoffs (499)
Legal (8718)
Lung cancer (273)
Manufacturing (257)
Medical device (13953)
Medtech (13958)
Mergers & acquisitions (20611)
Metabolic disorders (616)
Neuroscience (1867)
NextGen: Class of 2025 (7245)
Non-profit (4896)
Northern California (2139)
Obesity (344)
Opinion (248)
Patents (172)
People (62010)
Phase I (21754)
Phase II (30689)
Phase III (22816)
Pipeline (738)
Postmarket research (2938)
Preclinical (9313)
Radiopharmaceuticals (262)
Rare diseases (354)
Real estate (6479)
Regulatory (23927)
Research institute (2576)
Resumes & cover letters (454)
Southern California (1844)
Startups (3929)
United States (19362)
Vaccines (692)
Weight loss (256)
Date
Last 7 days (629)
Last 30 days (2606)
Last 365 days (36347)
2025 (4699)
2024 (37239)
2023 (42046)
2022 (53337)
2021 (58018)
2020 (56723)
2019 (49934)
2018 (37763)
2017 (34839)
2016 (34730)
2015 (40810)
2014 (34949)
2013 (30241)
2012 (32224)
2011 (32693)
2010 (30934)
Location
Africa (923)
Arizona (227)
Asia (43265)
Australia (7716)
California (4950)
Canada (1745)
China (413)
Colorado (223)
Connecticut (245)
Europe (95762)
Florida (709)
Georgia (168)
Illinois (497)
Indiana (269)
Maryland (790)
Massachusetts (3817)
Michigan (206)
Minnesota (353)
New Jersey (1394)
New York (1401)
North Carolina (952)
Northern California (2139)
Ohio (178)
Pennsylvania (1123)
South America (1302)
Southern California (1844)
Texas (728)
Utah (148)
Washington State (493)
753,462 Results for "sarepta therapeutics formerly known as avi biopharma inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Editorial
Sarepta, Biotech’s Regulatory Go-Getter, Signs Standout Rare Disease Deal
Not exactly known for its dealmaking, Sarepta Therapeutics has thrown down a massive wad of cash to work with Arrowhead Pharmaceuticals on RNAi-based medicines.
December 4, 2024
·
3 min read
·
Annalee Armstrong
Press Releases
Averna Therapeutics, formerly known as Exsilio Therapeutics, Appoints Thomas M. Barnes, Ph.D., as Chief Executive Officer
January 27, 2025
·
3 min read
Accelerated approval
Inspector General Questions FDA’s Accelerated Approval for Biogen, Sarepta Drugs
An OIG report zeroed in on what it said were three particularly problematic accelerated approvals: Biogen’s Aduhelm, Sarepta’s Exondys and Covis’ Makena.
January 15, 2025
·
2 min read
·
Tristan Manalac
Earnings
Sarepta Previews Q4 Findings, Touts Elevidys Earnings Beat
Sarepta Therapeutics’ Duchenne muscular dystrophy therapy Elevidys handily beat analysts’ expectations in the fourth quarter of 2024, reflecting the biotech’s “world-class” execution, according to BMO Capital Markets analysts.
January 14, 2025
·
2 min read
·
Tristan Manalac
Duchenne muscular dystrophy
Sarepta’s Recent Elevidys Presentations Leave Duchenne Community Wanting
With Sarepta’s gene therapy Elevidys now available to a majority of Duchenne muscular dystrophy patients, experts express cautious optimism while emphasizing the need for further data.
October 28, 2024
·
6 min read
·
Heather McKenzie
Press Releases
Sarepta Therapeutics Announces Inaugural $600 Million Senior Secured Revolving Credit Facility
February 17, 2025
·
4 min read
Press Releases
Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics
February 10, 2025
·
6 min read
Press Releases
Aspire Biopharma Holdings, Inc., Announces Public Listing on Nasdaq
February 20, 2025
·
5 min read
NextGen
BioSpace
’s NextGen Class of 2025 Leans Into Biopharma’s Hottest Trends
From ADCs and radiopharmaceuticals to cell and gene therapies, eager young startups are betting on advances in biopharma’s most competitive therapeutic spaces—and attracting dollars from Big Pharma.
January 7, 2025
·
5 min read
·
Heather McKenzie
Duchenne muscular dystrophy
Regenxbio Gears Up to Challenge Sarepta in DMD as Gene Therapy Advances to Pivotal Studies
Regenxbio is pushing its Duchenne muscular dystrophy gene therapy into pivotal development, with a BLA planned for 2026—potentially posing a threat to Sarepta’s Elevidys.
November 19, 2024
·
2 min read
·
Tristan Manalac
1 of 75,347
Next
